MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41420-021-00598-7

Медицинская библиотека · Cell death discovery · 2021

RNA-binding protein 39: a promising therapeutic target for cancer.

Xu Caipeng, Chen Xiaohua, Zhang Xuetian, Zhao Dapeng, Dou Zhihui, Xie Xiaodong, Li Hongyan, Yang Hongying, Li Qiang, Zhang Hong, Di Cuixia

СтатьяОбзорПеревод в очереди

Аннотация

RNA-binding motif protein 39 (RBM39), as a key factor in tumor-targeted mRNA and protein expression, not only plays a vital role in tumorigenesis, but also has broad development prospects in clinical treatment and drug research. Moreover, since RBM39 was identified as a target of sulfonamides, it has played a key role in the emerging field of molecule drug development. Hence, it is of great significance to study the interaction between RBM39 and tumors and the clinical application of drug-targeted therapy. In this paper, we describe the possible multi-level regulation of RBM39, including gene transcription, protein translation, and alternative splicing. Importantly, the molecular function of RBM39 as an important splicing factor in most common tumors is systematically outlined. Furthermore, we briefly introduce RBM39's tumor-targeted drug research and its clinical application, hoping to give reference significance for the molecular mechanism of RBM39 in tumors, and provide reliable ideas for in-depth research for future therapeutic strategies.

Для цитирования: Xu Caipeng, Chen Xiaohua, Zhang Xuetian, Zhao Dapeng, Dou Zhihui, Xie Xiaodong, Li Hongyan, Yang Hongying, Li Qiang, Zhang Hong, Di Cuixia. RNA-binding protein 39: a promising therapeutic target for cancer.. Cell death discovery. 2021. DOI: 10.1038/s41420-021-00598-7.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.